鍗靛发鐧岋紙Ovarian Cancer, OC锛夋槸瀵艰嚧濡囩鐧岀棁姝讳骸鐨勪富瑕佸師鍥犱箣涓€銆傛牴鎹浗闄呯檶鐥囩爺绌舵満鏋勭粺璁★紝2022骞村叏鐞冩柊鍙戝嵉宸㈢檶鐥呬緥绾︿负32.4涓囷紝姝讳骸浜烘暟绾�20.6涓�^{[1]<\/sup>銆備腑鍥芥柊鍙戠害6.1涓囦緥锛屾浜′汉鏁扮害涓�3.3涓囦緥^{[2]<\/sup>銆傚惈閾傚寲鐤楁槸杩涘睍鏈熷嵉宸㈢檶绯荤粺鎬ф不鐤楃殑棣栭€夈€傜害70%鐨勫嵉宸㈢檶鎮ｈ€呬細鍦ㄦ帴鍙楀惈閾傚寲鐤楀悗澶嶅彂锛屽苟鏈€缁堝彂灞曚负閾傝€愯嵂^{[3]<\/sup>銆傞搨鑰愯嵂鐧屾偅鑰呯洰鍓嶅皻缂轰箯鏈夋晥鐨勬不鐤楁墜娈碉紝鐜版湁璇佹嵁涓洪潪閾傚崟鑽寲鐤楄仈鍚堟垨涓嶈仈鍚堟姉琛€绠＄敓鎴愭不鐤楋紝ORR浠呯害4-13.2%锛屼腑浣嶆€荤敓瀛樻湡锛圤S锛変粎绾�10.9-14涓湀^{[4-8]<\/sup>銆傞搨鑰愯嵂鍚庡嵉宸㈢檶缂撳瓨鍦ㄥ法澶х殑鏈弧瓒崇殑涓村簥闇€姹傦紝鍥藉唴澶栨寚鍗椾腑鍧囨帹鑽愯繖閮ㄥ垎鎮ｈ€呭弬鍔犱复搴婅瘯楠屻€傛枃鐚姤閬撶害38%鐨勫嵉宸㈢檶鎮ｈ€呭瓨鍦℉ER2琛ㄨ揪^{[9]<\/sup>銆傜洰鍓嶅浗鍐呭皻鏃犱换浣曟姉HER2娌荤枟鑾锋壒鐢ㄤ簬HER2琛ㄨ揪鐨勫嵉宸㈢檶銆�<\/p> \n}}}}}

IBI354鏄姉HER2鍗曞厠闅嗘姉浣�-鍠滄爲纰辫鐢熺墿鍋惰仈鐗╋紝鍩轰簬淇¤揪鐢熺墿鎷ユ湁鑷富鐭ヨ瘑浜ф潈鐨勫垱鏂癆DC 鎶€鏈钩鍙般€傚熀浜庢ADC骞冲彴锛屼俊杈剧敓鐗╂鍦ㄦ帹杩涘娆捐嚜鐮擜DC鍒嗗瓙鐨勪复搴婅瘯楠岀爺绌讹紝骞跺睍鐜板嚭浼樺紓鐨勫畨鍏ㄦ€у拰鐤楁晥淇″彿銆�<\/p> \n

IBI354鑽墿鎶椾綋姣旓紙DAR锛夊€间负8锛岃兘澶熸惡甯︽洿澶氱殑姣掔礌杞借嵎鍒拌揪鑲跨槫缁嗚優锛汚DC鍒嗗瓙鍏锋湁鑹ソ鐨勪翰姘存€у拰浼樺紓鐨勪綋鍐匬K琛ㄧ幇锛涙瘨绱犲皬鍒嗗瓙鏈夊緢寮虹殑缁嗚優鑶滄笚閫忚兘鍔涳紝灞曠幇鍑烘洿濂界殑鏃佽鑰呮晥搴旓紱琛€娴嗕腑娓哥姣掔礌灏忓垎瀛愭祿搴︽瀬浣庯紝甯︽潵鏇翠綆鐨勮劚闈舵瘨鎬у拰鏇村ソ鐨勫畨鍏ㄦ€с€侷BI354涓嶄粎鍦ㄥ绉嶈嵎鐦よ嵂鐞嗗妯″瀷涓睍鐜板嚭浜嗚壇濂芥姉鑲跨槫娲绘€э紝鍦℉ER2闈跺悜娌荤枟鑰愯嵂鍜岃浆绉绘ā鍨嬩腑涔熻〃鐜板嚭浜嗙獊鍑虹殑鎶戠槫鏁堝姏銆�<\/p> \n

浠庝复搴婅揩鍒囬渶姹傚嚭鍙戯紝闄や簡宸茬粡寮€灞曠殑閾傝€愯嵂鍗靛发鐧孖II鏈熺爺绌讹紙HeriCare-Ovarian01锛夛紝淇¤揪鐢熺墿灏嗗竷灞€IBI354鍦ㄥ涓疄浣撶槫閫傚簲鐥囪繘琛屽紑鍙戙€�<\/p> \n

"濮嬩簬淇★紝杈句簬琛�"锛屽紑鍙戝嚭鑰佺櫨濮撶敤寰楄捣鐨勯珮璐ㄩ噺鐢熺墿鑽紝鏄俊杈剧敓鐗╃殑浣垮懡鍜岀洰鏍囥€備俊杈剧敓鐗╂垚绔嬩簬2011骞达紝鑷村姏浜庣爺鍙戙€佺敓浜у拰閿€鍞偪鐦ゃ€佽嚜韬厤鐤€佷唬璋€€佺溂绉戠瓑閲嶅ぇ鐤剧梾棰嗗煙鐨勫垱鏂拌嵂鐗╋紝璁╂垜浠殑宸ヤ綔鎯犲強鏇村鐨勭敓鍛姐€傚叕鍙稿凡鏈�15涓骇鍝佽幏寰楁壒鍑嗕笂甯傦紝瀹冧滑鍒嗗埆鏄俊杩埄鍗曟姉娉ㄥ皠娑诧紙杈句集鑸�^{®<\/sup>锛夛紝璐濅紣鐝犲崟鎶楁敞灏勬恫锛堣揪鏀稿悓^{®<\/sup>锛夛紝闃胯揪鏈ㄥ崟鎶楁敞灏勬恫锛堣嫃绔嬩俊^{®<\/sup>锛夛紝鍒╁Ε鏄斿崟鎶楁敞灏勬恫锛堣揪浼崕^{®<\/sup>锛夛紝浣╃背鏇垮凹鐗囷紙杈句集鍧�^{®<\/sup>锛夛紝濂ラ浄宸存浛灏肩墖锛堣€愮珛鍏�^{®<\/sup>锛夛紝闆疯帿瑗垮挨鍗曟姉娉ㄥ皠娑诧紙甯屽唹鎷�^{®<\/sup>锛夛紝濉炴櫘鏇垮凹鑳跺泭锛堢澘濡�^{®<\/sup>锛夛紝浼婂熀濂ヤ粦璧涙敞灏勬恫锛堢鍙嫃^{®<\/sup>锛夛紝鎵樿幈瑗垮崟鎶楁敞灏勬恫锛堜俊蹇呬箰^{®<\/sup>锛�, 姘熸辰闆峰鐗囷紙杈句集鐗�^{®<\/sup>锛夛紝鍖瑰Ε甯冩浛灏肩墖锛堟嵎甯曞姏^{®<\/sup>锛夛紝宸变簩閰镐粬闆锋浛灏艰兌鍥婏紙杈句集涔�^{®<\/sup>锛夊拰鍒╁巹鏇垮凹鐗囷紙濂ュ９鏂�^{®<\/sup>锛夊拰鏇垮Ε灏ゅ崟鎶桸01娉ㄥ皠娑诧紙淇″繀鏁�^{®<\/sup>锛夈€傜洰鍓嶏紝鍚屾椂杩樻湁3涓搧绉嶅湪NMPA瀹¤瘎涓紝4涓柊鑽垎瀛愯繘鍏II鏈熸垨鍏抽敭鎬т复搴婄爺绌讹紝鍙﹀杩樻湁15涓柊鑽搧绉嶅凡杩涘叆涓村簥鐮旂┒銆�<\/p> \n}}}}}}}}}}}}}}}

鍏徃宸蹭笌绀兼潵銆佺綏姘忋€佽禌璇鸿彶銆丄dimab銆両ncyte鍜孧D Anderson 鐧岀棁涓績绛夊浗闄呭悎浣滄柟杈炬垚30澶氶」鎴樼暐鍚堜綔銆備俊杈剧敓鐗╁湪涓嶆柇鑷爺鍒涙柊鑽墿銆佽皨姹傝嚜韬彂灞曠殑鍚屾椂锛岀鎵跨粡娴庡缓璁句互浜烘皯涓轰腑蹇冪殑鍙戝睍鎬濇兂銆傚骞存潵锛屽缁堝績鎬€绉戝鍠勫康锛屽潥瀹�"浠ユ偅鑰呬负涓績"锛屽績绯绘偅鑰呭苟鍏虫敞鎮ｈ€呭搴紝绉瀬灞ヨ绀句細璐ｄ换銆傚叕鍙搁檰缁彂璧枫€佸弬涓庝簡澶氶」鑽搧鍏泭鎻村姪椤圭洰锛岃瓒婃潵瓒婂鐨勬偅鑰呰兘澶熷緱鐩婁簬鐢熷懡绉戝鐨勮繘姝ワ紝涔板緱鍒般€佺敤寰楄捣楂樿川閲忕殑鐢熺墿鑽€傛埅鑷崇洰鍓嶏紝淇¤揪鐢熺墿鎮ｈ€呮彺鍔╅」鐩凡鎯犲強20浣欎竾鏅€氭偅鑰咃紝鑽墿鎹愯禒鎬讳环鍊�36浜垮厓浜烘皯甯併€備俊杈剧敓鐗╁笇鏈涘拰澶у涓€璧峰姫鍔涳紝鎻愰珮涓浗鐢熺墿鍒惰嵂浜т笟鐨勫彂灞曟按骞筹紝浠ユ弧瓒崇櫨濮撶敤鑽彲鍙婃€у拰浜烘皯瀵圭敓鍛藉仴搴风編濂芥効鏈涚殑杩芥眰銆�<\/p> \n

\n \n \n \n \n \n \n \n \n \n \n \n \n
鍙傝€冩枃鐚細<\/span><\/p> <\/td> \n <\/tr> \n
1.        Bray, F., et al., Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin, 2024. 74(3): p. 229-263.<\/span><\/p> <\/td> \n <\/tr> \n
2.        Han, B., et al., Cancer incidence and mortality in China, 2022. J Natl Cancer Cent, 2024. 4(1): p. 47-53.<\/span><\/p> <\/td> \n <\/tr> \n
3.        Armstrong, D.K., et al., NCCN Guidelines Insights: Ovarian Cancer, Version 1.2019. J Natl Compr Canc Netw, 2019. 17(8): p. 896-909.<\/span><\/p> <\/td> \n <\/tr> \n
4.        Gaillard S, Oaknin A, Ray-Coquard I, et al. Lurbinectedin versus pegylated liposomal doxorubicin or topotecan in patients with platinum-resistant ovarian cancer: A multicenter, randomized, controlled, open-label phase 3 study (CORAIL). Gynecol Oncol. 2021;163(2):237-245.<\/span><\/p> <\/td> \n <\/tr> \n
5.        Pujade-Lauraine E, Hilpert F, Weber B, et al. Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: The AURELIA open-label randomized phase III trial [published correction appears in J Clin Oncol. 2014 Dec 10;32(35):4025]. J Clin Oncol. 2014;32(13):1302-1308.<\/span><\/p> <\/td> \n <\/tr> \n
6.        Pujade-Lauraine E, Fujiwara K, Ledermann JA, et al. Avelumab alone or in combination with chemotherapy versus chemotherapy alone in platinum-resistant or platinum-refractory ovarian cancer (JAVELIN Ovarian 200): an open-label, three-arm, randomised, phase 3 study. Lancet Oncol. 2021;22(7):1034-1046.<\/span><\/p> <\/td> \n <\/tr> \n
7.        Cannistra SA. Evaluating new regimens in recurrent ovarian cancer: how much evidence is good enough?. J Clin Oncol. 2010;28(19):3101-3103.<\/span><\/p> <\/td> \n <\/tr> \n
8.        Naumann RW, Coleman RL. Management strategies for recurrent platinum-resistant ovarian cancer. Drugs. 2011;71(11):1397-1412.<\/span><\/p> <\/td> \n <\/tr> \n
9.        Yoon, J. and D.Y. Oh, HER2-targeted therapies beyond breast cancer - an update. Nat Rev Clin Oncol, 2024. 21(9): p. 675-700.<\/span><\/p> <\/td> \n <\/tr> \n <\/tbody> \n <\/table> \n<\/div> \n
<\/p>"]; $("#dvExtra").html(content_array[0]);})();